Nanoparticle News and Research RSS Feed - Nanoparticle News and Research

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.
Potential new treatment for sepsis and ARDS

Potential new treatment for sepsis and ARDS

Scientists at Queen's University Belfast are developing a potential revolutionary new treatment for Sepsis and Acute Respiratory Distress Syndrome (ARDS), which are among the leading causes of death in hospitalised patients in the UK. [More]
Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Northwestern University, a leader in cancer nanotechnology research, has received a five-year, $11.7 million grant from the National Cancer Institute to use nanotechnology to develop next-generation cancer treatments. [More]
Novel chemical virus can cross double lipid layer surrounding cells to release drugs

Novel chemical virus can cross double lipid layer surrounding cells to release drugs

Viruses are able to redirect the functioning of cells in order to infect them. Inspired by their mode of action, scientists from the CNRS and Université de Strasbourg have designed a "chemical virus" that can cross the double lipid layer that surrounds cells, and then disintegrate in the intracellular medium in order to release active compounds. [More]
EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. [More]
Researcher reveals link between inflammatory response of neutrophils and spread of oral cancer

Researcher reveals link between inflammatory response of neutrophils and spread of oral cancer

An abnormal immune response or "feedback loop" could very well be the underlying cause of metastases in oral cancers, according to Dr. Marco Magalhaes, Assistant Professor at the University of Toronto's Faculty of Dentistry and lead researcher in a study published in the journal Cancer Immunology Research. [More]
Einstein and Montefiore researchers receive $1.2 million grant to advance spinal cord injury research

Einstein and Montefiore researchers receive $1.2 million grant to advance spinal cord injury research

Researchers at Albert Einstein College of Medicine and Montefiore Health System have received a $1.2 million grant from New York State to advance their promising technology for treating paralysis and other effects of spinal cord injuries (SCI). [More]
Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors. [More]
Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University. [More]
First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases. [More]
New method helps determine titanium nanoparticles in sunscreen products

New method helps determine titanium nanoparticles in sunscreen products

Loads of cosmetics like sunscreen lotions contain titanium dioxide. These nanoparticles are contentious. Experts suspect they may have harmful effects on people and the environment. [More]
Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute, a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI's cancer Nanotechnology Laboratory (caNanoLab) data portal. [More]
Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells. [More]
Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. [More]
Scientists find way to create therapeutic heat to treat people suffering from chronic muscle pain

Scientists find way to create therapeutic heat to treat people suffering from chronic muscle pain

If you suffer from chronic muscle pain a doctor will likely recommend for you to apply heat to the injury. But how do you effectively wrap that heat around a joint? Korean Scientists at the Center for Nanoparticle Research, Institute for Basic Science in Seoul, along with an international team, have come up with an ingenious way of creating therapeutic heat in a light, flexible design. [More]
NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

A researcher at North Dakota State University, Fargo, is receiving a four-year $1.35 million research project grant from the National Cancer Institute of the National Institutes of Health to develop a targeted treatment for colorectal cancer. [More]
DGIST researchers set on creating microrobot-assisted procedure for dealing with blocked arteries

DGIST researchers set on creating microrobot-assisted procedure for dealing with blocked arteries

Swarms of microscopic, magnetic, robotic beads could be scrubbing in next to the world's top vascular surgeons--all taking aim at blocked arteries. [More]
Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Nanoparticles packed with chemotherapy drug and coated with chitosan target cancer stem-like cells

Nanoparticles packed with a clinically used chemotherapy drug and coated with an oligosaccharide derived from the carapace of crustaceans might effectively target and kill cancer stem-like cells, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Angiography and MPI: an interview with Professor Mauro Magnani University of Urbino

Angiography and MPI: an interview with Professor Mauro Magnani University of Urbino

I am Mauro Magnani, Professor of Biochemistry at the University of Urbino, Italy. My background is essentially the transition of activity from the lab to application. I am also the founder of a spin-off company called EryDel, which uses technology to load materials or drugs inside cells. [More]

What do cells really look like in 3D?

Nanolive SA, a start-up company founded in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, has developed a revolutionary microscope which allows for the very first time the exploration of a living cell in 3D without damaging it. [More]
Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection. [More]
Advertisement
Advertisement